The need for g-retroviral (gRV) vectors with a self-inactivating (SIN) design for clinical application has prompted a shift in methodology of vector manufacturing from the traditional use of stable producer lines to transient transfection-based techniques. Herein, we set out to define and optimize a scalable manufacturing process for the production of gRV vectors using transfection in a closed-system bioreactor in compliance with current good manufacturing practices (cGMP). The process was based on transient transfection of 293T cells on Fibra-Cel disks in the Wave Bioreactor. Cells were harvested from tissue culture flasks and transferred to the bioreactor containing Fibra-Cel in the presence of vector plasmid, packaging plasmids and calciumphosphate in Dulbecco's modified Eagle's medium and 10% fetal bovine serum. Virus supernatant was harvested at 10-14 h intervals. Using optimized procedures, a total of five ecotropic cGMP-grade gRV vectors were produced (9 liters each) with titers up to 3.6Â10 7 infectious units per milliliter on 3T3 cells. One GMP preparation of vector-like particles was also produced. These results describe an optimized process for the generation of SIN viral vectors by transfection using a disposable platform that allows for the generation of clinical-grade viral vectors without the need for cleaning validation in a cost-effective manner. Gene Therapy (2012) 19, 246-254; doi:10.1038/gt.2011.102; published online 14 July 2011
INTRODUCTION
Adverse events related to insertional mutagenesis and trans-activation of cellular proto-oncogenes in recent clinical trials for the treatment of X-linked severe-combined immunodeficiency [1] [2] [3] have led to the development of safety-enhanced self-inactivating (SIN) g-retroviral (gRV) vectors 4, 5 and lentiviral (LV) vectors. 6, 7 The SIN design, in which a deletion in the U3 enhancer-promoter region of the 3¢-long terminal repeat (LTR) renders both LTRs transcriptionally inactive after integration of the vector into the genome, has been shown to reduce the risk for insertional mutagenesis. [8] [9] [10] [11] Although LTR vectors allow for the efficient generation of clones of gRV vector-producing cells after transduction of a packaging cell line and stable integration of vectorproducing sequences, the same approach cannot be used for SIN gRV vectors. In SIN gRV vectors, transduction establishes U3 deletions in both proviral LTRs preventing genomic RNA to be produced in packaging cells. To address this, Loew et al. 12 described an elegant method in which stable producer clones for SIN gRV vectors were generated by inserting the vector backbone into a pre-defined chromatin locus using recombinant-mediated cassette exchanged and flprecombinase. This allowed for the generation of high-titer virusproducing clones that are less sensitive to silencing. Others have used a concatemeric array transformation technique to introduce SIN vector genomes into producer cells for the generation of hightiter LV vectors. 13 However, for clinical manufacturing, the use of stable producer lines requires the generation and certification of a master cell bank (MCB) for each vector to be produced, which is a lengthy and costly process, without guarantee that the selected and certified clone will remain stable over prolonged culture periods.
An alternative strategy to the use of stable producer cells is the production of vectors by transfection of a suitable cell line with vector and packaging plasmids. 14 The benefits of a transfection-based methodology for large-scale and clinical-grade vector production include: (1) flexibility, as changes in vector plasmid can be made without having to re-derive the producer cell line and/or generate a new MCB; (2) economy, avoiding certification of a specific stable producer line for each vector; (3) efficiency, as it circumvents frequently seen issues related to silencing of the inserted sequences in stable producer cells resulting in the loss of titer, and (4) time savings, as cloning, expanding and titering stable producers, as well as preparation and certification of the producer cell bank, can take months. An obvious drawback of using transfection is the presence of high amounts of plasmid DNA or cellular debris in the vector product. However, this limitation, as well as direct exposure of target cells to fetal bovine serum (FBS), can be overcome by preloading gRV vector particles on fibronectin before adding hematopoietic cells as described previously, 15 or, in the case of LV vectors, exposure of target cells to high levels of plasmid can be prevented by treating the vector product with benzonase before cell transduction. 16 Although transfection-based approaches may be less suitable for the production of the larger amounts of vector needed for phase 3 clinical trials, the benefits in time and cost savings for smaller early phase trials clearly outweigh the drawbacks. In fact, a large-scale good manufacturing practice (GMP)-grade LV vector for an early phase clinical trial for the treatment of Wiskott-Aldrich syndrome had been manufactured using a transfection-based protocol. 17 As recently reviewed by Wright, 18 the three transfection methods considered most relevant to large-scale production of clinical-grade viral vectors are DNA co-precipitation with calcium-phosphate (Ca-phosphate), 19 the use of polycations such as polyethylenimine, 20 and the use of cationic lipids. 21 Of the three, we evaluated Ca-phosphate, as it has continued to be used for transfection since its introduction 38 years ago, offering good transduction efficiencies in the presence and absence of serum for both adherent and nonadherent cells, with low toxicity and at low cost. 14 For the purpose of process development, Ca-phosphate-based transfection was compared with transfection using the cationic lipids, Lipofectamine and Fecturin.
A variety of bioreactor systems have been used for the production of high-titer gRV vectors from stable producer cells as described in a review by Merten. 22 Of the systems described, fixed-bed reactor culture systems consistently outperformed stirred tank reactors including microcarrier cultures. 23 A cell carrier that performed well in a fixed-bed reactor, and that had been used in the production of the first licensed gene therapy product in China, 24, 25 is Fibra-Cel. As Fibra-Cel had become available as a cell substrate for the Wave Bioreactor, 26 a fully disposable single-use closed-system bioreactor system, we set out to test whether this could be used to support gRV production by transfection.
Although significant advances in downstream processing of gRV vectors have been made in the past several years using chromatography-or centrifugation-based strategies, 27,28 the susceptibility of gRV vector particles to temperature, pH, ionic strength, shear stress and freeze-thaw cycles 29 have limited the purification and concentration strategies for large-scale clinical manufacturing. To support production of high-titer SIN gRV vectors by transfection without the need for further concentration, several modifications have been made to the viral backbone to improve RNA processing and increase titer of nonconcentrated vector stocks as described previously. 30 These include: retaining the splice donor site in the 5¢-untranslated region as this motif is important for high titer, most likely due to a role in mRNA export; 31 removing aberrant translational start codons; 31 and adding the post-transcriptional regulatory element (wPRE) of the woodchuck hepatitis virus to the 3¢-untranslated region UTR. 4, [32] [33] [34] Furthermore, to avoid silencing in target cells, vectors were also provided with a modified primer binding site that has been shown to escape epigenetic repressors. 35, 36 In this study, we utilized the improved viral backbones described above to develop a scalable process for large-scale manufacturing of high-titer current good manufacturing practice (cGMP)-grade virus for clinical use. We describe the development of such a process for the Wave Bioreactor platform. The development includes a comparison of adherent 293T-and suspension-based 293F cells, a comparison of transfection methods and temperatures, optimization of cell seeding density, timing of media change and optimization of plasmid concentration. Ultimately, we used our optimized protocol to produce and subsequently certify five (5) high-titer cGMP-grade ecotropic SIN gRV vectors in support of pre-clinical animal safety studies.
RESULTS

Cells and transfection
Suspension-adapted human embryonic kidney (HEK)293 cell-derived 293F cells were grown in serum-free FreeStyle 293 media and evaluated for growth and for the ability to produce gRV vector. Cells, when maintained at a density between 5Â10 5 and 2.5Â10 6 cells per ml, expanded for up to 10-fold over a period of 5 days with cell viabilities at or above 80%. Despite robust growth, when transfected with a gRV vector in suspension using either Lipofectamine or Fecturin, 293F cells produced vector with titers below the detection limit of 1Â10 3 infectious units (IU) ml À1 (data not shown). To be able to compare 293F cells with 293T cells side-by-side, both cell types were grown as adherent cells in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS. Titers of gRV vectors generated by 293F cells under adherent conditions were also below detection limit, whereas 293T cells transfected under the same conditions generated titers between 10 5 and 10 6 IU ml À1 (Figure 1a) . Although 293F cells were capable of producing LV vector, the titer generated in 293F cells was found to be 18-fold lower as compared with the titer generated in 293T cells. Of note, gRV transfections had not yet been optimized, which may account for gRV titers being lower than the LV vector titer. Vector titers generated in 293T cells in DMEM with 10% FBS were the highest when transfected with Ca-phosphate and 3-10-fold lower with Lipofectamine and Fecturin, respectively (Figure 1b) . Using Ca-phosphate, a comparison between 293F and 293F cells again showed that 293T cells generated titers that were higher than titers generated in 293F cells (1Â10 6 IU ml À1 for 293T versus 7Â10 4 IU ml À1 for 293F). On the basis of these data, 293T cells and Ca-phosphate were selected as the cell line and transfection method of choice for further optimization.
Cell substrate
Next, we evaluated Fibra-Cel as a cell substrate for 293T cells to enable production of vector in a scalable closed-system bioreactor. After seeding onto Fibra-Cel, 293T cells were found to grow within the matrix of the disks (Figure 2 ). When 293T cells that had been expanded on Fibra-Cel were compared with cells that had been expanded in tissue culture plastic, no difference in transient-transfection-derived gRV vector titer ( Figure 3a ) or difference in the total amount of virus produced (1.19Â10 7 IU with cells from T75 versus 1.20Â10 7 IU with cells from Fibra-Cel) could be observed. This indicates that expansion of cells on Fibra-Cel does not inhibit the ability of 293T cells to produce virus. As cells grown on Fibra-Cel cannot be quantitatively harvested and counted, glucose levels in the media were used as a surrogate measure to evaluate cell growth. When 293T cells were seeded onto Fibra-Cel in the Wave Bioreactor at a 1 l scale, and allowed to expand with a daily media change from days 3 to 7, glucose levels were found to decrease to a larger extent each day, indicating that metabolically active cells were expanding over time ( Figure 3b ). To determine the optimal time for transfection, cells were transfected with Ca-phosphate one day after seeding onto Fibra-Cel disks and compared with cells that had been transfected within 4 h of seeding. Cells transfected the day after seeding generated gRV vector with a titer of less than 10 4 IU ml À1 (data not shown), whereas cells that were transfected within 4 h of seeding generated gRV vector with a titer of 4.3Â10 5 IU ml À1 . Finally, when transfected at the time of seeding, 293T cells generated gRV vector at titers at the same order of magnitude up to 1.8Â10 5 IU ml À1 (Figure 3c ). When we analyzed vector harvested at 10/14 h intervals for up to 91 h post-transfection, cells transfected on Fibra-Cel produced 84 ± 2% (n¼9) of all virus within the first three vector harvests. This is comparable to cells transfected on tissue culture plastic, which produced 79 ± 2% (n¼34) of all virus within the first three harvests (Figure 3d ). Taken together, the data demonstrate that 293T cells are able to grow and expand on Fibra-Cel, and that gRV vector can be produced in a bioreactor using Ca-phosphate transfection when transfected within 4 h of seeding or at the time of seeding, and that the majority of virus can be collected starting at 24 h post-transfection within the first three sequential 10-14 h harvests.
Cell culture conditions
To further develop the bioreactor as a platform for the production of viral vectors by transfection, we set out to test several additional processing parameters including cell culture history, the timing of media change, and transfection and harvest temperature. To evaluate the effect of culture history on transfection of cells on Fibra-Cel, 293T cells were plated in tissue culture flasks between 1.25Â10 4 and 1Â10 5 cells per cm 2 and allowed to expand for 4 days. After 4 days, cells were harvested and the same amount of cells from each group (2Â10 8 cells) was added to 2 g of Fibra-Cel in 100 ml of media in the presence of Ca-phosphate and plasmid DNA. Surprisingly, cells that had been plated at the higher cell density before transfection produced up to 10 times as much gRV as compared with cells that had been plated at the lower density ( Figure 4a ). The main difference noted between the cultures was that cells that had initially been seeded at the lowest cell density were generally at 70-80% confluency at the time of harvest, whereas other groups were between 90 and 100% confluent. As in several experiments some cell peeling was observed in the groups expanded at the highest cell density, 5Â10 4 cells per cm 2 was chosen as the optimal density for cell expansion for large-scale cGMP production. Although intriguing, to date no mechanism has been delineated for the observed effect of producer cell history on titer, which will be the subject of future study. When the time interval between transfection and media change was varied from 12 to 43 h, optimal gRV titer was found to occur when cells were maintained in the presence of transfection mixture for 19 h (Figure 4b ). Finally, using the optimal cell density and time interval as defined above, we compared virus yields after transfection on Fibra-Cel and harvest at two commonly used temperatures, 32 and 37 1C. Unlike some stable producer lines that yield higher gRV vector titers at 32 1C, 37 transient transfection on Fibra-Cel yielded higher titers at 37 1C (Figure 4c ). On the basis of these data, all subsequent experiments were performed using a 5Â10 4 cells per cm 2 pre-transfection cell seeding density, using a 19 h time interval between transfection and media change, and a temperature of 37 1C for transfection and vector harvest.
Plasmid concentration
For transfection in tissue culture flasks, the optimal plasmid concentration had been determined empirically to be 2.3 mg total plasmid per ml with an optimal mass ratio of gRV vector, gag/pol and env of 4.0:3.6:1.6 (data not shown). Others have suggested that transfections, when scaling up from for culture flasks to multi-tray cell factories, can be scaled up proportionally. 38 However, for transfection in the bioreactor, we hypothesized that the optimal plasmid concentration as defined in tissue culture flasks may be limiting as Ca-phosphate complexes do not settle onto the cell layer as they do in static cultures. Our data show that the total amount of gRV vector produced on Fibra-Cel could be improved approximately threefold by increasing the plasmid concentration from 2.3 to 9.2 mg ml À1 (Figure 4d) . A comparison between two GALV-pseudotyped gRV vectors produced at a 1 l scale, one produced using 2.3 mg ml À1 of plasmid and one using 400x Figure 2 The 293T cells cultured on Fibra-Cel. Microscopic image of 293T cells on a Fibra-Cel disk. Disks had been rinsed with phosphate-buffered saline, treated with trypsin and rinsed in DMEM to remove the bulk of the cells. Cells were fixed with 70% isopropanol and stained with 0.4% Trypan blue (Â400).
9.2 mg ml À1 , showed a nearly 10-fold improvement in the total amount of infectious gRV produced, from 2.7Â10 8 to 2.1Â10 9 IU (Table 1) . When the same plasmid concentration was used to produce a gRV vector with an ecotropic envelope, the amount of infectious virus increased another 18-fold to 3.7Â10 10 IU, with a titer up to 1.5Â10 7 IU ml À1 . The ecotropic envelope was tested as it was the envelope of choice for vectors to be produced for murine safety studies. A further increase in plasmid concentration to 11.5 mg ml À1 improved the yield by only an additional 5.3% (data not shown). Hence, 9.2 mg ml À1 was chosen as the preferred plasmid concentration for use in the bioreactor as this resulted in close to maximum titer.
Time critical processes
Next, we tested two variables that have historically been considered to be time critical: the stability of the transfection mixture and the stability of the gRV vector post-harvest. In the first study, a transfection mixture containing a GALV-pseudotyped gRV vector encoding for green fluorescent protein (GFP) was prepared and diluted in DMEM with 10% FBS (one part mixture to three parts of medium).
Half of the diluted transfection mixture was added to 2Â10 7 cells without delay and the other half was maintained at ambient temperature for 1.5 h before addition to the cells (triplicate groups each). There was no significant difference in vector titer (Figure 5a ), indicating that this step may take as long as 1.5 h without affecting overall yield. To test vector stability after harvest, a GALV-pseudotyped gRV vector encoding for GFP was maintained at 2-8 1C or at ambient temperature for different time intervals. Similar to what has been reported by others, 39,40 the titer remained stable for up to 10 h at either temperature (Figure 5b ), indicating that the filling process, which may take up to several hours at ambient temperature before the vector can be stored at or below À70 1C, does not negatively affect the titer. Taken together, the data show that the additional time needed to transfect and process larger amounts of vector as a result of scale-up is not expected to negatively impact vector titer.
cGMP production The process optimized above was used for the successful manufacturing of five high-titer GMP-grade gRV vector products (Table 2 ) and one product with vector-like particles (data not shown) in a bioreactor containing Fibra-Cel. The vectors chosen were part of a panel designed to test the role of the LTRs and alternate internal promoters on insertional mutagenesis in an animal model. 41 Briefly, 293T cells from a previously established and certified MCB (293T.MCB-6007) were expanded in complete culture media (CCM) consisting of DMEM SRS11.SF.GFP.pre* (GALV pseudotyped; n¼4), RSF91.DsRed2.pre* (Eco pseudotyped; n¼2), SRS11.SF.DsRed2.pre* (Eco and GALV pseudotyped, n¼30) and SRS11.EFS.IL2RG.pre* (Eco, GALV, RD114 pseudotyped, n¼7). (Figure 6 ). At 4 days before transfection, cells were plated at a cell density of 5Â10 4 cells per cm 2 . On the day of transfection, 6Â10 9 cells were harvested, mixed with Ca-phosphate transfection reagents and plasmid (12.0 mg of vector, 10.8 mg of pCDNA3.MLVg/p and 4.8 mg of ecotropic envelope; total plasmid concentration 9.2 mg ml À1 ) in the presence of 25 mM chloroquine, and transferred to a Wave Bioreactor bag containing Fibra-Cel in CCM in a total volume of 3 l. After 19 h, the bioreactor was rinsed with phosphate-buffered saline containing cations and replaced with fresh CCM. Vector was subsequently collected at three 12-h intervals (9 l total), and stored in Cryocyte bags at À80 1C. In a recent paper, À80 1C was described to be adequate for storage of gRV vector for up to 10 years without loss of infectivity. 42 In our hands, unconcentrated vector titers ranged from 1.5Â10 6 to 3.6Â10 7 IU ml À1 (Table 2) . Each final product was further tested for sterility and endotoxin, for the absence of mycoplasma, in vitro adventitious agents and replication-competent retrovirus, and for the level of residual plasmid and genomic DNA in compliance with FDA guidances for cellular and gene therapy products as described previously. 43, 44 
DISCUSSION
We herein describe the development of a novel and scalable manufacturing platform for the transient production of cGMP-grade gRV vector using Ca-phosphate transfection. The platform is based on the Wave Bioreactor that uses disposable bags and closed-system processing technology that can be scaled-up from 0.1 to 500 l without the need for sterilization or validated cleaning between runs. 26 To accommodate adherent 293T cells, we employed Wave bags supplemented with FibraCel carriers, a substrate that had previously been used for the world's first commercially licensed adenovirus gene therapy product produced in the New Brunswick Scientific (Edison, NJ, USA) CelliGen Plus Packed-Bed Bioreactor. 24, 25 Using the Wave Bioreactor, we were able to manufacture and certify five gRV vector lots with vector titers ranging from 1.5Â10 6 to 3.6Â10 7 IU ml À1 . In support of these data, others reported to have successfully used Fibra-Cel in a packed bed reactor for the production of gRV vector from a stable producer cell line. 23 Large-scale manufacturing using transfection requires careful analysis and optimization of processing steps as both the transfection process and collection of vector are time-dependent and affected by a number of variables as demonstrated in this study. Among the variables tested, several were found to be critical, including the cell density at which cells are seeded before harvest for transfection. Although others have indicated that failure to generate and maintain production cells in optimally 'receptive' conditions can result in a greater than 10-fold decrease in specific productivity, 18 the effect of culture history on transfection has remained largely anecdotal. Although a mechanism remains to be established, we have defined the optimal cell seeding density for 293T cells to be cultured before transfection to be 5Â10 4 cells per cm 2 . Whether the effect of cell density on titer holds true for other vector types and whether this is specific to gRV vectors remains to be investigated. Other variables that were found to affect vector titer include the time at which the medium is changed post-transfection and the concentration of plasmid used in the transfection procedure. In our hands, 19 h was the optimal time point, whereas 9.2 mg ml À1 was found to be the optimal plasmid concentration for transfection in the bioreactor. This is in contrast to transfection in T-75 tissue culture flasks where increasing the amount of plasmid from 46 to 92 mg per flask actually decreased viral titer (JCMvdL, unpublished data). Our data are similar to the previously reported results on LV vector generation by transfection of 293T cells. 45 Abbreviations: CCM, complete culture media; Eco, ecotropic envelope; GALV, gibbon ape leukemia virus envelope; gRV, g-retroviral; ND, not determined. The 293T cells were seeded into the Wave Bioreactor at 2Â10 9 cells in 1 l of CCM in the presence of plasmid (as indicated), calcium-phosphate transfection reagent and polybrene. The media were changed at 19-h post-transfection and vector was harvested at three 12-h time points (H1, H2, H3, vector harvests 1, 2, 3, respectively). Infectious titers were determined on HT1080 cells (vectors with GALV envelope) and NIH 3T3 cells (vector with ecotropic envelope). a Vector produced using standard conditions. b Vector produced using optimized conditions. Abbreviations: cGMP, current good manufacturing practices; Eco, ecotropic envelope; gRV, g-retroviral; ND, not determined; PBS, phosphate-buffered saline. cGMP-grade gRV vectors produced in support of murine genotoxicity studies by calcium-phosphate transfection on Fibra-Cel disks in the Wave Bioreactor using 6Â10 9 cells from a 293T master cell bank (293T.MCB-6007), 12 mg of vector plasmid, 10.8 mg of gag/pol and 4.8 mg of ecotropic envelope plasmid in 3 l of media (total plasmid concentration 9.2 mg ml À1 ) in the presence of chloroquine. The bioreactor was rinsed with PBS and media were changed at 19 h post-transfection and vector was harvested at three 12-h intervals (harvests 1-3). Infectious titers were determined on NIH 3T3 cells.
In this study, 293T cells generated higher vector titers than 293F suspension cells even when compared under comparable adherent conditions. The lower titer in 293F cells may have been caused by the absence of the SV40 large T antigen, which has been shown to improve LV production in human HEK293 cells. 46 An alternative to 293F cells is the 293FT cell line, a suspension cell line derived from 293F that expresses SV40 large T antigen under the human cytomegalovirus (CMV) promoter. 47 However, 293FT cells also express the neomycin resistance gene and are to be maintained in the presence of antibiotics, making this line unsuitable for the production of clinical-grade vector.
Others have compared 293T with other HEK293 derivatives such as the 293FT cells, and reported 293T cells to be superior for LV vector production. 17 Several groups have developed methods for the production of large-scale gRV vectors using adherent cells in roller bottles or cell factories, 39, 48, 49 as well as in fixed-bed reactors such as the CellCube, 23, 39 or on microcarriers. 50 High-density fixed-bed reactors, including the Celligen reactor that uses Fibra-Cel carriers, generated higher vector titers as compared to low-density culture systems. 23 We have now shown that Fibra-Cel carriers can also be used as an effective cell substrate in a Wave Bioreactor for the production of gRV vectors using Ca-phosphate transfection of 293T cells generating non-concentrated titers as high as 3.6Â10 7 IU ml À1 .
In closing, the data presented here summarize the optimization of a novel manufacturing platform for the large-scale production of SIN gRV vector using transient transfection. Although the optimized parameters had been applied successfully to the production of five different vectors, it is possible that a change in vector expression cassette or envelope may require additional but limited process development for full optimization. Importantly, using the processes described, we were able to generate and certify large-scale cGMP-grade gRV vector for clinical use. Despite the need for careful process development, the transient transfection-based platform, once developed, allows for maximal flexibility and cost and time savings in large-scale clinical vector production for the production of both gRV and LV vectors in the fast-moving field of gene therapy.
MATERIALS AND METHODS Plasmids
gRV vectors and the LV vector used in this study were generated by Drs C Baum and A Schambach. The gRV vectors produced for genotoxicity studies were SERS11.EGFP.pre*, SRS11.EFS.EGFP.pre*, SERS11.SF.EGFP.pre*, RSF91.EGFP.pre* and RSF91.uORF.EGFP.pre*. The uORF element was provided by Jens Bohne. The plasmid used for production of the IL2Rg vector was SRS11.EFS.IL2Rg.pre* as described previously. 8 Additional vectors used for development included SIN11.SF.eGFP.pre*, SRS11.SF.GFP.pre*SE and SRS11.SF.GFP.pre*. The MIEG3 gRV vector was cloned in the laboratory of D Williams. Plasmids encoding for the gag and pol sequences included pCDNA3.MLVg/p for all gRV vectors and pCDNA3.g/p.4ÂCTE for the LV vector (courtesy: C Baum and A Schambach). Envelope plasmids used included pHCMV-RD114 (K84; courtesy: Dr F Cosset), pHCMV-VSV-G (M75; courtesy: Dr C Baum), pHCMV-GALVenv (K83; courtesy: Dr W Beyer) and K73-Eco (courtesy: Dr T Kitamura). Ccc-grade plasmids used for cGMP manufacturing were produced by the PlasmidFactory (Bielefeld, Germany) as described previously. 51 Cell culture and media HEK293 cell-derived 293T cells (ATCC, Manassas, VA, USA) were thawed and expanded in DMEM supplemented with 10% FBS. During expansion, cells were split on a semi-weekly basis and plated at a cell density of 1-5Â10 4 cells per cm 2 . The 293T cells were cryopreserved in DMEM 10564 supplemented with 25% (vol vol À1 ) FBS and 10% (vol vol À1 ) dimethyl sulfoxide (Sigma, St Louis, MO, USA). For clinical vector production, a cGMP MCB of 293T cells was prepared as described above and certified (293T.MCB-6007). Non-adherent HEK293 cell-derived 293F cells (Invitrogen, Carlsbad, CA, USA) were thawed and expanded in serum-free FreeStyle293 media (Invitrogen) and cryopreserved in FreeStyle293 medium supplemented with 25% (vol vol À1 ) FBS and 10% (vol vol À1 ) dimethyl sulfoxide (Sigma). Glucose levels were measured using an Accu-Chek Glucose Monitor. 
End-of-Production
• Collect end-of-production cells • Aliquot and freeze cells at or below -140°C • Send out samples for certification Figure 6 Clinical manufacturing flow chart. Manufacturing process followed for the manufacturing of five cGMP-grade gRV vectors produced in the Wave Bioreactor (as listed in Table 2 ).
slowly bubbling air through the HEPES-buffered saline solution. For the bioreactor, the plasmid mixture included 4 mg of vector, 3.6 mg of gag/pol and 1.6 mg of envelope per liter (9.2 mg ml À1 ), unless indicated otherwise. For transfection in tissue culture plastic, optimal plasmid amounts were 10 mg of vector, 9 mg of gag/pol and 4 mg of envelope per T-75 flask in 10 ml of culture media (2.3 mg ml À1 ). Following bubbling, the transfection mixture was incubated for 20 min at ambient temperature and added to the cells. Transfections with Lipofectamine 2000 and Fecturin were performed according to the manufacturer's instructions. Briefly, plasmid DNA and Lipofectamine or Fecturin were each diluted in OptiPro (Invitrogen); the DNA solution and the solution with either Lipofectamine or Fecturin were combined, incubated for 20 min at room temperature and added to the cells. After mixing with transfection reagent, cells were plated in tissue culture flasks or seeded onto Fibra-Cel in the presence of 25 mM chloroquine (Sigma). The medium was changed 19 h post-transfection and vector was collected at 10-14 h intervals as indicated, filtered through a 0.45 mm filter (Millipore, Billerica, MA, USA) and stored at or below À70 1C.
gRV production in the bioreactor
Cells from a certified 293T MCB were expanded on tissue culture plastic, harvested, mixed with Ca-phosphate transfection reagents and plasmid as described above, and pumped into a 2 or 20 l Wave Cell Bag (GE Healthcare, Piscataway, NJ, USA) containing Fibra-Cel disks (New Brunswick) in DMEM with 10% FBS in the presence of 25 mM chloroquine (Sigma) as described previously. 30 Cells were cultured at 37 1C, 5% CO 2 using a rocking speed of 22 r.p.m. and 61 angle for the bioreactor. At 19 h post-transfection, the medium was exchanged; gRV was harvested at approximately 12-h intervals, filtered through an RCQT leukocyte reduction filter (Pall, Ann Arbor, MI, USA) and aliquoted into Cryocyte freezing containers (Miltenyi Biotec, Auburn, CA, USA) using a closed-system fluid path. Cryocyte bags were placed in protective freezing cassettes (Biomedical Marketing Associates, Wexford, PA, USA) and stored at or below À70 1C.
Titration
Titers of vectors pseudotyped with an ecotropic envelope were determined in mouse NIH 3T3 cells (ATCC No. TIB-180) based on eGFP expression; titers of vectors pseudotyped with a GALV or feline leukemia virus (RD114) envelope were determined in human HT1080 cells (ATCC No. CCL-121) based on eGFP expression. Briefly, cells were seeded at 2Â10 4 cells per well in a 24-well plate and exposed for 4 h or overnight to serial dilutions of vector in 0.5 ml in the presence of 8 mg ml À1 polybrene (Aldrich Chemical Co., Milwaukee, WI, USA). After 48-96 h, cells were analyzed by flow cytometry for the expression of eGFP and titers (IU ml À1 ) were calculated based on the number of cells at the time of infection, the dilution and percent GFP + cells. For titration of vectors without GFP, transduced cells were carried and split for an additional 12-14 days, DNA was harvested and titer was determined by quantitative polymerase chain reaction using wPRE primers as described below.
Quantitative real-time PCR
For titer determination by quantitative polymerase chain reaction, genomic DNA was isolated from transduced cells after 12-14 days of cell expansion using the Gentra Puregene Cell and Tissue Kit (Qiagen, Valencia, CA, USA) as per the manufacturer's protocol. Quantitative polymerase chain reaction was performed on an ABI 7900 HT sequence detection system (Applied Biosystems, Foster City, CA, USA) in a multiplexed reaction detecting wPRE and human ApoB sequences concurrently. The wPRE sequence present in the vector was detected using oligonucleotides 5¢-TGTATAAATCCTGGTTGCTGTC-3¢ and 5¢-GCACACCACGCCACGTTG-3¢, and 5¢-6-FAM/TTATGAGGAGTTGTGGCC CGTTGT/3BHQ1-3¢ as a probe. Human ApoB genomic sequence was detected using 5¢-TGAAGGTGGAGGACATTCCTCTA-3¢ and 5¢-CTGGAATTGCGATT TCTGGTAA-3¢, and 5¢-VIC/CGAGAATCACCCTGCCAGACTTCCGT/Tamra. A linear regression was made from each target gene standard curve and used for calculating the average number of vector copies per cell. Serial dilutions of genomic DNA derived from clone A5, a HT1080 cell line-derived single-copy clone containing the wPRE target sequence, was used as a reference.
Microscopy
Post-transfection, Fibra-Cel disks containing expanded 293T cells were treated with TrypLESelect for 30 min at 37 1C to remove excess cells, rinsed with phosphate-buffered saline, fixed for 5 min with 70% isopropanol and stained with 0.4% Trypan blue (Sigma).
Statistical analysis
P-values were determined by Student's t-test.
